ClinicalTrials.gg
Not yet recruitingNCT07615413Updated May 29, 2026

Phase 1 Study of HS-10541 as Monotherapy or in Combination With Other Anti-cancer Therapies in Patients With KRAS G12C Mutation Advanced Solid Tumors.

A Phase 1 interventional study of HS-10541 in KRAS G12C Mutation Advanced Solid Tumor, sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-29.

Sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd. (part of Hansoh Pharmaceutical Group Company Limited) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
636
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a multicenter, open-label phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of HS-10541 as monotherapy or in combination with other anti-cancer therapies in participants with KRAS G12C mutation advanced solid tumors.

02

Conditions studied

  • KRAS G12C Mutation Advanced Solid Tumor
03

In context

Lead sponsor

Jiangsu Hansoh Pharmaceutical Co., Ltd. is the lead sponsor of 138 studies on the registry; 72 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntary participation and written ..
  2. Aged 18 years or older (≥18 years), of any gender.
  3. or cytologically confirmed advanced solid tumor.
  4. At least one according to v1.1.
  5. PS of 0 to 1, with no deterioration within 2 weeks prior to the first dose.
  6. With a > 12 weeks.
  7. Adequate bone marrow reserve and organ function.
  8. Female participants of and non-sterilized male participants must agree to use highly effective measures from the time of signing the ICF until 6 months after the last dose.
  9. Female participants of childbearing potential must be non-lactating; all female participants must have a negative pregnancy test prior to the first dose.

Exclusion criteria

Exclusion Criteria:

  1. Uncontrolled pleural effusion, pericardial effusion, or abdominal effusion requiring clinical intervention.
  2. Presence of symptomatic , /brainstem involvement, history of intracranial hemorrhage or intraspinal hemorrhage, or spinal cord compression.
  3. Unresolved ≥grade 2 toxicities from previous anticancer therapy.
  4. History of a second primary
  5. Severe, uncontrolled, or active cardiovascular or cerebrovascular diseases, or severe cardiac examination abnormalities.
  6. Severe or poorly controlled diabetes mellitus or hypertension.
  7. Known active infectious diseases.
  8. gastrointestinal dysfunction.
  9. Gastrointestinal obstruction or perforation occured.
  10. Interstitial lung disease (ILD).
  11. Participants with known or to any active or inactive ingredients of the study drug, chemically similar drugs, or drugs of the same class.
  12. Other inappropriate situation considered by the investigator.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
636 participants (estimated)

Study arms

  • Experimental
    HS-10541

    Participants in all subjects will receive HS-10541

    Drug: HS-10541

Interventions

  • DrugHS-10541

    HS-10541 will be administered orally once daily in a continuous regimen

06

What researchers measure

Primary outcomes

  1. Dose-limiting toxicity (DLT)

    Number of participants with dose limiting toxicities.

    Time frame: From Cycle 1 Day 1 through Day 21. A cycle is 21 days.

  2. Adverse events (AEs)

    Incidence and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) from the date of first dose to 28 days (monotherapy) or 90 days (combination therapy) after the final dose (or as specified in the protocol).

    Time frame: Approximately 1.5 years.

  3. Objective response rate (ORR)

    Defined as the percentage of participants with a best overall response of partial response or better per response evaluation criteria in solid tumors (RECIST 1.1).

    Time frame: Approximately 1.5 years.

  4. Progression-free survival (PFS)

    Defined as from the date of first dose to the date of disease progression according to investigator assessment or death due to any cause, whichever occurs first.

    Time frame: Approximately 1.5 years

Secondary outcomes

  1. PK profile of HS-10541as monotherapy, or combination therapy

    The maximum concentration (Cmax)

    Time frame: Pre-dose and postdose up to end of treatment, approximately 1.5 years.

  2. PK profile of HS-10541as monotherapy, or combination therapy

    Time to the maximum concentration (Tmax)

    Time frame: Pre-dose and postdose up to end of treatment, approximately 1.5 years

  3. PK profile of HS-10541as monotherapy, or combination therapy

    Area under the concentration time curve from time zero (pre-dose) to last time of quantifiable concentration (AUC0-t)

    Time frame: Pre-dose and postdose up to end of treatment, approximately 1.5 years

  4. PK profile of HS-10541as monotherapy, or combination therapy

    Area under the concentration time curve from time zero to infinity (AUC0-∞)

    Time frame: Pre-dose and postdose up to end of treatment, approximately 1.5 years.

  5. ORR

    Defined as the percentage of participants with a best overall response of partial response or better per response evaluation criteria in solid tumors (RECIST 1.1).

    Time frame: Approximately 1.5 years.

  6. Disease control rate (DCR)

    Defined as the percentage of participants with a best overall response of stable disease or better per RECIST 1.1.

    Time frame: Approximately 1.5 years.

  7. Duration of response (DoR)

    Defined as the time from date of first documented evidence of partial response or better to the date of disease progression or death due to any cause

    Time frame: Approximately 1.5 years

  8. PFS

    Defined as from the date of first dose to the date of disease progression according to investigator assessment or death due to any cause, whichever occurs first.

    Time frame: Approximately 1.5 years

  9. Overall Survival (OS)

    Defined as the time from date of first dose to the date of death due to any cause

    Time frame: Approximately 3 years.

  10. Adverse events (AEs)

    Incidence and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) from the date of first dose to 28 days (monotherapy) or 90 days (combination therapy) after the final dose (or as specified in the protocol).

    Time frame: Approximately 1.5 years.

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2026; primary completion for Jun 2029, 36 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2026
First posted
May 29, 2026
StartEst.
Jun 30, 2026
Primary completionEst.
Jun 30, 2029
CompletionEst.
Dec 30, 2029
Last update
May 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07615413
Responsible party
Sponsor
First posted
May 29, 2026
Start date
Jun 30, 2026 (estimated)
Primary completion
Jun 30, 2029 (estimated)
Completion
Dec 30, 2029 (estimated)
Last update
May 29, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion